Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.19.3.a.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Revenue $ 7,159 $ 10,722 $ 23,730 $ 33,865
Cost of revenue 4,379 6,132 16,125 19,147
Gross profit 2,780 4,590 7,605 14,718
Operating expenses        
Research and development 1,222 1,736 4,227 5,011
Sales and marketing 1,556 1,999 6,147 6,012
General and administrative 1,093 1,738 3,706 4,672
Intangible amortization 308 830 924 2,652
Restructuring Charges 234 0 234 0
Total operating expenses 4,413 6,303 15,238 18,347
Operating profit (loss) (1,633) (1,713) (7,633) (3,629)
Other income, net 109 158 398 442
Income (loss) before income taxes (1,524) (1,555) (7,235) (3,187)
Income tax benefit (expense) (20) (1) (27) (11)
Net income (loss) from continuing operations (1,544) (1,556) (7,262) (3,198)
Income from discontinued operations, net of tax [1]       (138)
Net income (loss) (2) [2] $ (1,544) $ (1,556) $ (7,262) $ (3,336)
Basic net income (loss) from continuing operations $ (0.10) $ (0.10) $ (0.47) $ (0.21)
Basic net income (loss) from discontinued operations 0.00 0.00 0.00 (0.01)
Basic (0.10) (0.10) (0.47) (0.21) [3]
Diluted net income (loss) from continuing operations (0.10) (0.10) (0.47) (0.21)
Diluted net income (loss) from discontinued operations 0.00 0.00 0.00 (0.01)
Diluted $ (0.10) $ (0.10) $ (0.47) $ (0.21) [3]
Weighted-average number of common shares outstanding:        
Basic (shares) 15,575 15,524 15,514 15,576
Effect of dilutive securities: restricted stock, restricted stock units, performance stock units and stock options (4) [4] 0 0 0 0
Diluted (shares) 15,575 15,524 15,514 15,576
[1] See Note 1 for additional information regarding discontinued operations.
[2] Net income (loss) and comprehensive income (loss) are the same for the periods reported.
[3] Per share amounts may not sum to totals due to rounding.
[4] The Company had 1.0 million and 0.9 million shares represented by common stock equivalents for the three and nine months ended December 31, 2019, respectively, and 1.1 million and 1.0 million for the three and nine months ended December 31, 2018, respectively, which were not included in the computation of average dilutive shares outstanding because they were anti-dilutive. In periods with a net loss from continuing operations, the basic loss per share equals the diluted loss per share as all common stock equivalents are excluded from the per share calculation.